X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare VENUS REMEDIES with AJANTA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs AJANTA PHARMA - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    VENUS REMEDIES AJANTA PHARMA VENUS REMEDIES/
AJANTA PHARMA
 
P/E (TTM) x -524.2 18.6 - View Chart
P/BV x 0.1 7.5 2.0% View Chart
Dividend Yield % 0.0 0.8 -  

Financials

 VENUS REMEDIES   AJANTA PHARMA
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-17
AJANTA PHARMA
Mar-16
VENUS REMEDIES/
AJANTA PHARMA
5-Yr Chart
Click to enlarge
High Rs1431,720 8.3%   
Low Rs651,103 5.9%   
Sales per share (Unadj.) Rs324.2194.6 166.6%  
Earnings per share (Unadj.) Rs6.445.2 14.2%  
Cash flow per share (Unadj.) Rs40.650.3 80.7%  
Dividends per share (Unadj.) Rs08.00 0.0%  
Dividend yield (eoy) %00.6 0.0%  
Book value per share (Unadj.) Rs366.0132.0 277.2%  
Shares outstanding (eoy) m12.3488.77 13.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.37.3 4.4%   
Avg P/E ratio x16.231.2 51.9%  
P/CF ratio (eoy) x2.628.1 9.1%  
Price / Book Value ratio x0.310.7 2.7%  
Dividend payout %017.7 0.0%   
Avg Mkt Cap Rs m1,282125,299 1.0%   
No. of employees `0000.9NA-   
Total wages/salary Rs m2512,570 9.8%   
Avg. sales/employee Rs Th4,430.1NM-  
Avg. wages/employee Rs Th278.0NM-  
Avg. net profit/employee Rs Th87.6NM-  
INCOME DATA
Net Sales Rs m4,00017,275 23.2%  
Other income Rs m23166 13.7%   
Total revenues Rs m4,02317,442 23.1%   
Gross profit Rs m7855,807 13.5%  
Depreciation Rs m422451 93.6%   
Interest Rs m34449 702.9%   
Profit before tax Rs m425,474 0.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-371,460 -2.5%   
Profit after tax Rs m794,014 2.0%  
Gross profit margin %19.633.6 58.4%  
Effective tax rate %-87.926.7 -329.5%   
Net profit margin %2.023.2 8.5%  
BALANCE SHEET DATA
Current assets Rs m2,6067,639 34.1%   
Current liabilities Rs m1,9802,715 72.9%   
Net working cap to sales %15.628.5 54.9%  
Current ratio x1.32.8 46.8%  
Inventory Days Days12843 296.8%  
Debtors Days Days4379 54.8%  
Net fixed assets Rs m5,3536,914 77.4%   
Share capital Rs m123177 69.8%   
"Free" reserves Rs m4,39311,442 38.4%   
Net worth Rs m4,51611,721 38.5%   
Long term debt Rs m1,618149 1,088.2%   
Total assets Rs m8,29114,814 56.0%  
Interest coverage x1.1112.9 1.0%   
Debt to equity ratio x0.40 2,824.3%  
Sales to assets ratio x0.51.2 41.4%   
Return on assets %5.127.4 18.6%  
Return on equity %1.834.2 5.1%  
Return on capital %6.346.5 13.5%  
Exports to sales %055.1 0.0%   
Imports to sales %18.46.0 306.4%   
Exports (fob) Rs mNA9,527 0.0%   
Imports (cif) Rs m7361,038 71.0%   
Fx inflow Rs m010,422 0.0%   
Fx outflow Rs m7361,678 43.9%   
Net fx Rs m-7368,744 -8.4%   
CASH FLOW
From Operations Rs m9973,264 30.6%  
From Investments Rs m-461-2,093 22.0%  
From Financial Activity Rs m-571-1,186 48.2%  
Net Cashflow Rs m-35-15 237.2%  

Share Holding

Indian Promoters % 32.9 73.8 44.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.2 1.6 11.6%  
FIIs % 0.6 7.6 7.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 66.4 17.0 390.6%  
Shareholders   20,121 20,968 96.0%  
Pledged promoter(s) holding % 36.4 4.4 828.2%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare VENUS REMEDIES With:   DR. DATSONS LABS  STRIDES SHASUN LTD  TTK HEALTHCARE  JUBILANT LIFE SCIENCES  DISHMAN PHARMA  

Compare VENUS REMEDIES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Volatile Day Flat; Auto Stocks Top Gainers(Closing)

After opening the day in green, share markets in India witnessed volatile trading activity throughout the day and ended the day on a positive note.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

My Top Five Stocks After the Karnataka Elections(The 5 Minute Wrapup)

May 16, 2018

The markets seem confused. They're neither going up nor down. What should investors do? Consider Safe Stocks. Here's the top 5 Safe Stocks in the market today.

How A Storm Destroyed Rain Industries... And a Superb Small Cap Stock I Recommend(Profit Hunter)

May 17, 2018

A mutual fund regulation could cause small cap prices to tank - If you haven't been paying attention to your small caps - now is the time to catch the opportunities that start pouring in.

Has the Indian Home Buyer Become Smarter?(Vivek Kaul's Diary)

May 17, 2018

Home loans continue to grow, despite falling sales. What explains this phenomenon?

Looking Beyond the Colourful Prism of This Airline Company(Sector Info)

May 10, 2018

Can Interglobe Aviation Safely Fly Out of Turbulence?

HDFC Prudence Fund Now HDFC Balanced Advantage Fund - Time To Sell?(Outside View)

May 9, 2018

PersonalFN provides detail analysis on HDFC Balanced Advantage Fund (erstwhile HDFC Prudence Fund and HDFC Growth Fund).

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


May 22, 2018 (Close)

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES - AJANTA PHARMA COMPARISON

COMPARE VENUS REMEDIES WITH

MARKET STATS